SEC Form 4 · accession 0001562180-18-004338

REGENXBIO Inc. · RGNX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Stephen Yoo

Officer — Chief Medical Officer

Period of report

Oct 29, 2018

Accepted (ET)

Oct 31, 2018 · 4:22 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001590877

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Oct 29, 2018	M	20,414	$0.85	A	20,414	D
Common Stock^F2	Oct 29, 2018	S	3,042	$59.83	D	17,372	D
Common Stock^F3	Oct 29, 2018	S	1,700	$60.66	D	15,672	D
Common Stock^F4	Oct 29, 2018	S	2,100	$61.82	D	13,572	D
Common Stock^F5	Oct 29, 2018	S	8,026	$62.93	D	5,546	D
Common Stock^F6	Oct 29, 2018	S	5,446	$63.67	D	100	D
Common Stock	Oct 29, 2018	S	100	$64.42	D	0	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F7	$0.85	Oct 29, 2018	M	20,414	D	—	Nov 3, 2024	Common Stock	20,414	102,072	D

Explanation of responses

F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2This transaction was executed in multiple trades at prices ranging from $59.26 to $60.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3This transaction was executed in multiple trades at prices ranging from $60.26 to $61.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4This transaction was executed in multiple trades at prices ranging from $61.28 to $62.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5This transaction was executed in multiple trades at prices ranging from $62.285 to $63.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6This transaction was executed in multiple trades at prices ranging from $63.29 to $64.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7The previously granted option, representing a right to purchase a total of 247,900 shares, became exercisable as follows: 165,200 of the shares subject to the option are initial shares ("Initial Shares") and 82,700 of the shares subject to the option are contingent shares ("Contingent Shares"). 23,600 of the Initial Shares vested on October 13, 2014, 35,400 of the Initial Shares vested on October 13, 2015 and an additional 2,950 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 15% of the Contingent Shares were deemed vested as of October 13, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following October 13, 2014, with 25% of the remaining 85% of Contingent Shares having vested on October 13, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter.